

Or Yat Sun  
Form 4  
March 04, 2019

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Or Yat Sun

2. Issuer Name and Ticker or Trading Symbol  
ENANTA PHARMACEUTICALS  
INC [ENTA]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/01/2019

\_\_\_\_ Director  
 Officer (give title below) Sr. VP & CSO  
\_\_\_\_ 10% Owner  
\_\_\_\_ Other (specify below)

C/O ENANTA  
PHARMACEUTICALS, INC., 500  
ARSENAL STREET

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

WATERTOWN, MA 02472

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)	
				Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2019		S <sup>(1)</sup>		5,910	D		\$ 103.3211
								304,763
Common Stock	03/01/2019		S <sup>(1)</sup>		4,090	D		\$ 103.8368
								300,673

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form**

SEC 1474  
(9-02)

displays a currently valid OMB control number.

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned (Instr. 5)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Or Yat Sun C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN, MA 02472			Sr. VP & CSO	

## Signatures

/s/ Nathaniel S. Gardiner as attorney-in-fact 03/01/2019

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2016
- (2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$102.66 to \$103.62, inclusive.
- (3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$103.66 to \$104.20, inclusive.

### Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. TD VALIGN="bottom"> Nuveen New York Performance Plus Muni Fund, Inc. " " "

**2a. To approve a new sub-advisory agreement between Nuveen Fund Advisors and Nuveen Asset Management, LLC.**

**FOR AGAINST ABSTAIN FOR AGAINST ABSTAIN** 01 Nuveen Connecticut Premium Income Municipal Fund " " " 02 Nuveen Georgia Dividend Advantage Muni Fund 2 " " " 03 Nuveen Intermediate Duration Municipal Term Fund " " " 04 Nuveen Intermediate Duration Quality Muni Term Fund " " " 05 Nuveen Maryland Premium Income Municipal Fund " " " 06 Nuveen Missouri Premium Income Municipal Fund " " " 07 Nuveen North Carolina Premium Income Muni Fund " " " 08 Nuveen Virginia Premium Income Municipal Fund " " " 09 Nuveen New York Dividend Advantage Muni Fund " " " 10 Nuveen New York Dividend Advantage Muni Fund 2 " " " 11 Nuveen New York Performance Plus Muni Fund, Inc. " " "

**2b. To approve a new sub-advisory agreement between Nuveen Fund Advisors and NWQ Investment Management Company, LLC.**

Not Applicable

**2c. To approve a new sub-advisory agreement between Nuveen Fund Advisors and Symphony Asset Management LLC.**

**FOR AGAINST ABSTAIN FOR AGAINST ABSTAIN** 01 Nuveen Floating Rate Income Fund " " " 02 Nuveen Floating Rate Income Opportunity Fund " " " 03 Nuveen Senior Income Fund " " "

**2d. To approve a new sub-advisory agreement between Nuveen Fund Advisors and Advisory Research, Inc.**

Not Applicable

**2e. To approve a new sub-advisory agreement between Nuveen Fund Advisors and Spectrum Asset Management Inc.**

Not Applicable

**3a. Election of Board Members:** To withhold authority to vote for any individual nominee(s) mark the For All Except and write the nominee number(s) on the line provided.

- 01. William Adams IV
- John K. Nelson
- 02. Nelson
- 03. Thomas S. Schreier, Jr.

	<b>FOR</b>	<b>WITHHOLD</b>	<b>FOR ALL</b>		<b>FOR</b>	<b>WITHHOLD</b>	<b>FOR ALL</b>		
	<b>ALL</b>	<b>ALL</b>	<b>EXCEPT</b>		<b>ALL</b>	<b>ALL</b>	<b>EXCEPT</b>		
01 Nuveen Connecticut Premium Income Municipal Fund	..	..	..	_____	02 Nuveen Floating Rate Income Fund	..	..	..	_____

Edgar Filing: Or Yat Sun - Form 4

03 Nuveen Floating Rate Income Opportunity Fund	..	..	..	_____	04 Nuveen Georgia Dividend Advantage Muni Fund 2	..	..	..	_____
05 Nuveen Maryland Premium Income Municipal Fund	..	..	..	_____	06 Nuveen Missouri Premium Income Municipal Fund	..	..	..	_____
07 Nuveen North Carolina Premium Income Muni Fund	..	..	..	_____	08 Nuveen Senior Income Fund	..	..	..	_____
09 Nuveen Virginia Premium Income Municipal Fund	..	..	..	_____					

**3b. Election of Board Member:**

03. Thomas S.  
Schreier, Jr.

	<b>FOR WITHHOLD</b>		<b>FOR WITHHOLD</b>
01 Nuveen Intermediate Duration Municipal Term Fund	.. ..	02 Nuveen Intermediate Duration Quality Muni Term Fund	.. ..
03 Nuveen New York Dividend Advantage Muni Fund	.. ..	04 Nuveen New York Dividend Advantage Muni Fund 2	.. ..

**Important Notice Regarding the Availability of Proxy Materials for the Special**

**Meeting of Shareholders to Be Held on August 5, 2014.**

**The Proxy Statement for this meeting is available at:**

**<http://www.nuveenproxy.com/ProxyInfo/CEF/Default.aspx>**

**IMPORTANT: PLEASE SIGN AND DATE BEFORE MAILING.**

